Lessening involvement of Treg in suppressive CD39/CD73 adenosine pathway is likely compensated by alternative adenosine pathway involving NAD(+)-consuming enzyme CD38 which is active in the BM niches of myeloma (55) and correlates with progression of myeloma (Figure 1) (56). This evidence concerns the gene ENTPD1 and plasma cell myeloma.